FDL169

FDL169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector being developed by Flatley Discovery Lab for treating cystic fibrosis (CF) patients who carry the F508del mutation, the most common mutation in this disease. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.


Cat. No.: EX-A3163	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	770	In-stock
500mg	1050	In-stock
1g	1550	In-stock
5g	3850	In-stock
10g	6600	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	CFTR corrector 2
CAS No.	1628416-28-3
Purity	>98%
Formula	C27H23FN4O4
Mol Weight	486.4943
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Matos AM, Matos P. J Lung Health Dis (2018) 2(1):9-16. Combination therapy in Phe508del CFTR: how many will be enough. Journal of lung health and diseases.
CoA	CoA of FDL169

Smiles:	O=C(N(C)C1=CC=C2N=C(C)OC2=C1)CN(N=C(C3=CC=CC(F)=C3)C4=C5C=C(OCC)C=C4)C5=O


		Search